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Evaluating the Quality of Randomized Controlled Trials that
Examine the Efficacy of Natural Health Products: A Systematic
Review of Critical Appraisal Instruments
Anne Marie Whelan, Tannis M. Jurgens and Lindsay Lord
College of Pharmacy, Dalhousie University, Dalhousie University, 5968 College Street, Halifax NS,
Canada B3H 3J5
The purpose of this project was to conduct a systematic review to identify instruments designed
to evaluate the quality of randomized controlled trials (RCTs) of natural health products
(NHPs). Instruments were examined for inclusion of items assessing methods, identity and
content of the NHP, generalizability of results and instructions for use. Online databases,
websites, textbooks and reference lists were searched to identify instruments. Relevance
assessment and data extraction of articles were completed by two investigators and
disagreements were settled by the third investigator. Data were analyzed using descriptive
statistics. Of the 4442 citations identified, 29 were potentially relevant with 16 meeting the
criteria for inclusion. None of the instruments stated they were validated; content in the four
areas of interest varied considerably. The most common items included randomization sequence
generation (100%), blinding (100%), allocation concealment (75%) and participant flow (75%).
Only nine of the NHP instruments included at least one item to appraise the specific content of
the NHP. The CONSORT Statement for Herbal Interventions most closely addressed the four
areas of interest; however, this instrument was specific for herbs. There is a need for the
development of a validated instrument for assessment of the quality of RCTs that would be
useful for herbs as well as other NHPs.
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Introduction
Natural sourced medicines, such as herbal products,
have become increasingly popular among consumers
who search for ‘natural’ ways to maintain their health.
In Canada, natural sourced medicines are called natural
health products (NHPs) and are classified by Health
Canada to include all herbal remedies, traditional
medicines, homeopathic medicines, probiotics, amino
acids, essential fatty acids, vitamins and minerals that
are appropriate for over the counter selection (1).
Consumers often ask health care providers for guidance
on the safe and effective use of NHPs.
When providing recommendations to consumers, health
care providers are accustomed to following principles
of evidence based medicine, which includes, in part, con-
sidering data from research reports that have been assessed
on their quality of reporting of research methodology,
design and analysis of data (2). Increasingly, randomized
controlled trials (RCTs), considered the ‘gold standard’
when evaluating the efficacy of conventional medicines (3),
are being used to evaluate the efficacy of NHPs (4).
Therefore, it is essential for health care providers and
their patients that reports of RCTs of NHPs be critically
appraisedwiththesamerigorasisappliedtotheassessment
of the quality of RCTs of conventional medications.
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properly cited.Two kinds of critical appraisal instruments have been
developed specifically to aid the evaluation of the quality
of evidence produced by RCTs of conventional medica-
tions (5,6). Many of these instruments focus on evaluat-
ing the methodological quality of the trial, examining
how the design, conduct and analysis of the RCT
minimize biases (e.g. selection, measurement) (7). Other
instruments focus on the quality of the report itself;
examining the information provided regarding the design,
conduct and analysis of the results (8).
A critical appraisal instrument useful for evaluating the
quality of evidence provided by RCTs of NHPs would
include all components found in critical appraisal
instruments for conventional medications, as well as
questions to assess the quality of reporting of data that is
specific to NHPs. Medicines from natural sources are
predisposed to significant variation in chemical content
as a consequence of how they are grown and/or pro-
cessed. The resulting qualitative and/or quantitative
variation in chemical content of NHPs can have a
direct effect on their pharmacological effects and subse-
quently on the outcome of the RCT in which they are
being evaluated (9,10). Adequate reporting of the identity
and chemical content of the specific NHP that is being
evaluated in the RCT is critical if the results of the trial
are to be applicable to other brands or preparations of
the NHP. Other factors that are unique to NHPs and can
affect the quality of the results of an RCT, may be the
appearance, smell and taste of the NHP. Therefore
correctly blinding an RCT by creating a placebo that is
identical in every way to the test NHP is very important.
Thus, to adequately appraise the results of an RCT of an
NHP, the optimal instrument would include items to
assess the identity of the NHP (and its placebo) being
evaluated. It would also include questions to help the
user determine if the results of the RCT could be applied
to other patients and to other products made from the
same plant or other natural source. This ability to help
the user determine the generalizability of the trial results
would facilitate the translation of the research results for
application to practice situations (11). It is also important
that instructions for how to use the critical appraisal
instrument are provided to help ensure that the user is
interpreting the questions or items in the instrument
correctly (12).
The purpose of this project was to conduct a systematic
review to identify and analyze instruments designed for
critically appraising RCTs that evaluate the efficacy of
NHPs. Instruments were examined to determine if
they adequately addressed four components: quality of
methods, details of the identity and content of the NHP
tested, generalizability of results to other patients and
other preparations of the NHP and instructions for use
of the instrument. Additionally they were examined
to determine if the instruments had been validated.
Thus, the first objective of this project was to identify
published critical appraisal instruments designed to assess
the quality of RCTs evaluating the efficacy of NHPs.
The second objective was to systematically review the
appraisal instruments to document the inclusion of items
in each instrument that examined the following: the
methodological quality of the trial; the identity and
content of the NHP and placebo; and the applicability of
trial results to clinical practice. The third objective was to
determine how each appraisal instrument had been
developed, if it had been validated and if instructions
for use were provided.
Methods
Retrieval of Articles
Database searches were performed (PubMed, Embase,
Web of Science, CINAHL, IPA and Cochrane Library)
up to September 2006 to locate potentially relevant
articles describing the critical appraisal of RCTs of
NHPs. Search terms were: critical appraisal, scale,
checklist, instrument, tool, form, randomized controlled
trial, natural health product, herbs, botanical, plant
preparation, dietary supplement, complementary therapy,
evidence based medicine, quality control, quality assess-
ment and standards. Searches were limited to English
language articles, with no restrictions on publication
dates. Textbooks, files of the investigators and websites
of evidence-based medicine (13) were examined for
additional instruments. Finally, bibliographies of relevant
references were examined for additional citations.
Relevance Assessment
All potentially relevant articles were retrieved and
screened to determine relevance to study objectives by
two investigators (T.J. and L.L.), using a form developed
specifically for this purpose. Articles were deemed
relevant if they met at least one of the following inclusion
criteria: they contained instruments used for the appraisal
of RCTs of NHPs; they detailed how to report RCTs of
NHPs; or they discussed the importance of quality
assessment of NHP trials and provided suggested items
of importance. Articles were not considered relevant
if they met at least one of the following exclusion criteria:
the instrument was meant for the assessment of
meta-analyses, systematic reviews, or any trial design
other than RCT; the instrument was not published in a
journal, textbook or on a website; or the instrument
was designed for the assessment of RCTs of therapies
other than NHPs, e.g. surgery. If the same instrument
was identified from several resources, it was included
only once.
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A form was developed to aid data extraction. The first part
of the form was a checklist comprised of items contained in
the CONSORT Statements, including those items specific
to herbs found in the CONSORT Statement for Herbal
Intervention (14). Using the CONSORT Statements
provided a good starting point for the data extraction
form as they consist of lists of criteria deemed to be
importantinthereportingofanRCTsuchthatareaderwill
understand how a trial was conducted and be able to assess
the validity of results. Additionally, the CONSORT
Statements provide detailed explanation of the meaning
of the criteria used, which would aidthe accurate extraction
of data (12,14,15). Following the itemized extraction
portion, the data extraction form contained an area for
recording additional items found in instruments but not
contained in the CONSORT Statements. These were
termed miscellaneous items.
In the second section of the data extraction form, the
articles were categorized by type of instrument (checklist,
rating scale, numeric scale, combination of checklist and
scale) or as a guidance document. The term guidance
document was adapted from a previous publication and
in this project was intended to capture articles that
described how to report an RCT or discussed the
importance of assessing publication quality and provided
example items for consideration (7). The method used to
develop the instrument, any process used for validation
and provision of instructions for use, were also recorded.
Two investigators (A.M.W. and L.L.) independently
completed data extraction for all articles. Disagreements
were resolved by the third investigator (T.J.).
Analysis
Data were analyzed using descriptive statistics. The
identified instruments were separated into categories
based on whether they were a type of instrument (check-
list, numeric scale, rating scale, combination checklist and
scale) or a guidance document. A list of items contained
in instruments was compiled and the number of instru-
ments that included each item was tabulated.
Miscellaneous items were also tabulated. Methods of
development and validation were examined to identify
the most common processes used. References cited as a
source of instrument development were reviewed to
determine if the same pool of instruments were used as
a basis for instrument development.
Results
Article Retrieval and Relevance Assessment
Online database searches and hand searching of
investigators files, websites, textbooks and reference
lists identified 4442 citations (Fig. 1). Of these, 4032
citations were excluded after initial review indicated
they were not pertinent to the project. Review of the
remaining 410 abstracts identified a total of 29 potentially
relevant articles, 16 of which met the inclusion criteria
(14,16–30). Of the 16 instruments 6 were checklists,
3 combinations of a scale and a checklist, 3 rating scales
and 4 numeric scales. No guidance documents specific to
NHPs were identified.
Data Extraction
Items
In the 16 instruments developed specifically for use with
NHPs, the most common items included randomization
sequence generation (100%), blinding (100%), allocation
concealment (75%), participant flow (75%) and baseline
data (50%) (Fig. 2). Nine of these instruments included
at least one item to appraise the identity or content of
the NHP (14,17,18,20–22,25,29,30). Only 4 of the 16
instruments included items pertaining to the general-
izability of the results (14,18,20,27). Twelve items not
found in the CONSORT Statements were extracted from
the instruments for NHPs and recorded as miscellaneous
items (Table 1).
Instrument Development, Validation and Guidelines
for Use
A description of the method used to develop the
instrument was provided for a total of 12 of the 16
instruments (75%). Eleven of the instruments that
reported method of development were adapted or
modified from one or more existing instruments and
one was developed as a result of a discussion of experts.
The most common references cited as sources for
modification/adaptation for new instrument development
are listed in Table 2.
None of the 16 instruments stated that they had been
validated. Instructions for using critical appraisal instru-
ments were included with four of the identified instru-
ments (14,18,21,25).
Discussion
As anticipated, there was a paucity of instruments
for the critical appraisal of RCTs evaluating the
efficacy of NHPs. The CONSORT Statement for
Herbal Interventions (14) most closely addressed
the four components (quality of methods, details of the
identity and content of NHP tested, generalizability of
results and instructions for use) felt to be important in
such an instrument. However, the CONSORT Statement
for Herbal Interventions had two limitations. It was
designed for use exclusively with herbal medicines, and
eCAM 2009;6(4) 443therefore was not useful for the other non-herbal types
of NHPs and there was no indication that the
CONSORT Statement for Herbal Interventions had
been validated for use as an instrument for critically
appraising an RCT.
There was a wide variety in the number and wording of
the items included in the identified appraisal instruments.
As well as the items contained in the CONSORT
Statement for Herbal Interventions, an additional
12 unique miscellaneous items were extracted from the
instruments. This illustrated the lack of apparent
consensus on which items are essential for inclusion
in a critical appraisal instrument. Encouragingly, there
was evidence that the most common items found
(e.g. randomization sequence generation (31) blinding
(31–34), allocation concealment (31–33) and participant
flow (35–37) have been shown to be important in
minimizing bias in trials and/or in improving the quality
of reporting. Additionally, each of these items was part
of validated instruments used with conventional medica-
tions (38–41). This provides good rationale for inclusion
of items in critical appraisal instruments.
Surprisingly, seven of the 16 instruments developed for
use with NHPs did not contain any items to address the
identity and content of the NHPs being tested. An
adequate appraisal of the design and results of an RCT
of an NHP must include an assessment of the informa-
tion provided in the report of the RCT detailing the
identity and chemical content of the NHP tested in the
trial. Documenting the name of the NHP that was
evaluated is not always sufficient to ensure unambiguous
identity of the NHP, as it is well known that the chemical
Database searches and hand searching
4442 citations reviewed 
410 abstracts reviewed
29 articles reviewed
4032 citations 
excluded: not relevant
381 abstracts
excluded: not relevant 
13 articles were excluded because instrument:
- was intended for therapies other than NHPs: 6
-was published in more than one source: 5
- was not designed for RCTs: 1
- was not published: 1
6 checklists 
4 numeric
scales  
3 combination
scales and
checklists
3 rating scales  
16 instruments 
Figure 1. Results of literature search and relevance assessment.
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preparations, thus affecting the pharmacological effects
of the product (9,10). Most importantly, documenting the
detailed identity of the NHP used in the RCT allows an
interested person to select a product of similar content
and be able to expect similar outcomes.
Since there did not appear to be a gold standard appraisal
instrument for RCTs of NHPs, it was important to
determine how instruments were developed and how
items were chosen for inclusion in instruments.
Approximately 75% of the articles that were identified
provided information about how the instrument was
developed. Of those who reported their development
techniques, almost 70% were adapted or modified from
existing instruments. The instrument that was published
by Jadad et al. (40). was most commonly used as a
templateforthedevelopmentofotherinstruments.Someof
the references cited were used to develop only one other
instrument. This may suggest that authors are selecting
their preferred existing instrument and then modifying
it to meet their needs. However, in the new instruments
developed from previous instruments, there was little
specific information provided as to why an item was
included/excluded or how/why the item was modified.
Thus there appeared to be minimal empirical basis for
the development of many of the instruments. Although
none of the instruments stated that they were validated, six
of the instruments were adapted from the validated
instrument published by Jadad et al. (40). However,
in most cases, it was the non-validated instruments that
were used as a starting point for the development of
new instruments, meaning that potential problems with
existing instruments are being perpetuated in the newly
created instruments. It was discouraging to see that
only 25% of the identified instruments included some
instructions for use. Guidance in using the instrument
as the developers intended should provide some
consistency in the interpretation of items and therefore
less variability in results obtained from the use of the
instrument.
Strengths and Limitations
To our knowledge this is the first article to systematically
review the literature to identify instruments for the
critical appraisal of RCTs evaluating efficacy of NHPs.
02468 1 0 1 2 1 4 1 6
1. Title and Abstract
2. Background
3. Participants
4a. Herbal Medicinal Product Name
4b. Characteristics of Herbal Product
4c. Dosage Regimen and Quantitative Description
4d. Qualitative Testing
4e. Placebo/Control Group
4f. Practitioner
5. Objectives
6. Outcomes
7. Sample Size
8. Sequence Generation
9. Allocation Concealment
10. Implementation
11a. Blinding (Masking)
11b. Success of Blinding
12. Statistical Methods
13. Participant Flow
14. Recruitment
15. Baseline Data
16. Numbers Analyzed
17. Outcomes and Estimation
18. Ancillary Analysis
19. Adverse Effects
20. Interpretation
21. Generalizability
22. Overall Evidence
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Figure 2. Frequency of items included in instruments for assessing quality of RCTs of NHPs.
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design exist, we limited our review to only instruments
designed to assess quality of RCTs as the efficacy of
NHPs are being increasingly evaluated using this
methodology.
Although we followed systematic review methodology
as rigorously as possible when conducting this research
we did encounter difficulties particularly with regards to
literature searching. Selecting search terms to use to
identify relevant articles in various databases proved
problematic, as indexing terms varied considerably
between databases. It is possible that some instruments
may not have been identified as search terms were not
exhaustive. It also appeared as though MeSH headings
were not very effective at identifying desired articles. As a
result, text word searching was used, which resulted in
many hits that were deemed to be irrelevant to the
research. For example, using the term ‘instrument’
resulted in articles that pertained to implements/tools
used for surgery or other procedures and were not at all
relevant to our study. Similar difficulties were also
encountered by the Agency for Healthcare Research
and Quality (7). We followed their suggestions of not
relying only on literature searches, and used published
reports, such as theirs, to identify existing instruments.
In the end, we did find that many articles, not identified
through database searching, were located by hand
searching the reference lists of other articles.
Due to resource constraints we were not able to search
non-English literature or contact other researchers/
experts in this field for identification of other potential
instruments. It is possible that instruments were missed
by not searching in languages other than English.
However, we believe we were able to identify many of
the commonly used instruments, as the same instru-
ments began to appear repeatedly in the databases we
searched and in the hand searching of reference
lists. These are likely the same instruments that would
also be found by any health care provider trying to find
a critical appraisal instrument for use in practice or
research. Thus, despite the limitations we have
described, we believe that we were able to identify and
review the most readily available assessment instruments
for RCTs of NHPs.
Conclusion
Although this systematic review was successful in
identifying appraisal instruments for evaluating the
quality of RCTs of NHPs, none of those identified
were widely accepted as the gold standard instrument.
The CONSORT Statement for Herbal Interventions
comes closest to fulfilling requirements for a quality
instrument to critically appraise RCTs of NHPs, however
it’s limitation is that it is specific for herbal medicines.
There is therefore a need for the development and
validation of an instrument that can be used to reliably
assess the quality of results of RCTs of any NHPs,
whether herbs or single, natural sourced chemicals.
Empirical evidence and results of this review suggest
that randomization sequence generation, allocation con-
cealment, blinding and participant flow are four elements
that improve the quality of an RCT and should be
included as items in a critical appraisal instrument. Items
pertaining specifically to the identity and content of
NHPs as well as applicability of results to practice must
be included. It remains to be determined if a group of
items specific to NHPs could be developed, validated and
added to an existing gold standard instrument used for
assessing quality of trials of conventional medication or
whether an instrument specific for assessing trials of
NHPs will need to be developed.
Table 1. Miscellaneous items that appeared in instruments for critical
appraisal of RCTs of NHPs
Item Number of
times item
appeared
Enough detail for reanalysis by reader/study replicable 3
Intervention described in detail 2
Groups treated equally 1
Compliance 1
Indication for further intervention 1
Components known to be predictive of clinical effect? 1
Possibility of publication bias 1
Is journal peer-reviewed? 1
Informed consent/ethics approval 1
Syndrome of disease based on Chinese herbal medicine 1
Rationale of Chinese herbal medication composition 1
Selection bias after allocation 1
Table 2. References
a cited most frequently as source for adapting/
modifying for instrument development
Reference Number of
times cited
Jadad et al. (40) 6 (38%)
Moher et al. (revised CONSORT) (15) 3 (19%)
JAMA Users’ guides 1993–94 (11,42,43) 3 (19%)
Schulz et al. (44) 2 (13%)
Cochrane handbook (45) 2 (13%)
Juni et al. (46) 2 (13%)
Meinert et al. (47) 1 (6%)
Linde et al. (48) 1 (6%)
aSome articles reported more than one reference used as a source.
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